Clinical Trials Directory

Trials / Completed

CompletedNCT02948582

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single-Dose, 6-Way Crossover Study to Assess Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebuliser in Patients With COPD

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Sunovion Respiratory Development Inc. · Industry
Sex
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The study assessed the safety and ability of an orally inhaled medicine \[i.e., Glycopyrrolate Inhalation Solution = GIS\] to improve airflow in the lungs when delivered using an eFlow nebulizer in 42 patients with Chronic Obstructive Pulmonary Disease (COPD). Each patient randomly received several, single doses of GIS, or placebo, separated by approximately 1 to 2 weeks. After the dose was given, lung airflow was measured over 24 hours and blood was collected to measure how much GIS was in the bloodstream. The study was conducted to find the once-a- day GIS dose that produced the highest improvement in lung airflow using the eFlow nebulizer.

Conditions

Interventions

TypeNameDescription
DRUGGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
DRUGGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 50μg via eFlow, once daily
DRUGGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 100μg via eFlow, once daily
DRUGGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 200μg via eFlow, once daily
DRUGGlycopyrrolate Inhalation Solution 400μgGlycopyrrolate Inhalation Solution 400μg via eFlow, once daily
DRUGPlacebo 0.5mLPlacebo 0.5mL via eFlow, once daily

Timeline

Start date
2010-07-01
Primary completion
2010-11-01
Completion
2010-11-01
First posted
2016-10-28
Last updated
2018-03-12
Results posted
2018-03-12

Source: ClinicalTrials.gov record NCT02948582. Inclusion in this directory is not an endorsement.